» Articles » PMID: 34885217

Preferred Lung Cancer Screening Modalities in China: A Discrete Choice Experiment

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 10
PMID 34885217
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to identify preferred lung cancer screening modalities in a Chinese population and predict uptake rates of different modalities. A discrete choice experiment questionnaire was administered to 392 Chinese individuals aged 50-74 years who were at high risk for lung cancer. Each choice set had two lung screening options and an option to opt-out, and respondents were asked to choose the most preferred one. Both mixed logit analysis and stepwise logistic analysis were conducted to explore whether preferences were related to respondent characteristics and identify which kinds of respondents were more likely to opt out of any screening. On mixed logit analysis, attributes that were predictive of choice at 1% level of statistical significance included the screening interval, screening venue, and out-of-pocket costs. The preferred screening modality seemed to be screening by low-dose computed tomography (LDCT) + blood test once a year in a general hospital at a cost of RMB 50; this could increase the uptake rate by 0.40 compared to the baseline setting. On stepwise logistic regression, those with no endowment insurance were more likely to opt out; those who were older and housewives/househusbands, and those with a health check habit and with commercial endowment insurance were less likely to opt out from a screening programme. There was considerable variance between real risk and self-perceived risk of lung cancer among respondents. Lung cancer screening uptake can be increased by offering various screening modalities, so as to help policymakers further design the screening modality.

Citing Articles

Public Heterogeneous Preferences for Low-Dose Computed Tomography Lung Cancer Screening Service Delivery in Western China: A Discrete Choice Experiment.

Tao W, Bao T, Gu T, Pan J, Li W, Li R Int J Health Policy Manag. 2024; 13:8259.

PMID: 39099484 PMC: 11369360. DOI: 10.34172/ijhpm.8259.


A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.

Zhao Z, Gu S, Yang Y, Wu W, Du L, Wang G BMC Cancer. 2024; 24(1):73.

PMID: 38218803 PMC: 10787978. DOI: 10.1186/s12885-023-11800-7.


Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption.

Poon C, Wilsdon T, Sarwar I, Roediger A, Yuan M Front Public Health. 2023; 11:1264342.

PMID: 38026274 PMC: 10666168. DOI: 10.3389/fpubh.2023.1264342.


Patient Preferences in Diagnostic Imaging: A Scoping Review.

Baird T, Wright D, Britto M, Lipstein E, Trout A, Hayatghaibi S Patient. 2023; 16(6):579-591.

PMID: 37667148 DOI: 10.1007/s40271-023-00646-7.


Public Preference Heterogeneity and Predicted Uptake Rate of Upper Gastrointestinal Cancer Screening Programs in Rural China: Discrete Choice Experiments and Latent Class Analysis.

Liu R, Li Q, Li Y, Wei W, Ma S, Wang J JMIR Public Health Surveill. 2023; 9:e42898.

PMID: 37428530 PMC: 10366669. DOI: 10.2196/42898.


References
1.
Wortley S, Wong G, Kieu A, Howard K . Assessing stated preferences for colorectal cancer screening: a critical systematic review of discrete choice experiments. Patient. 2014; 7(3):271-82. DOI: 10.1007/s40271-014-0054-3. View

2.
Bridges J . Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2004; 2(4):213-24. View

3.
Colditz G, Atwood K, Emmons K, Monson R, Willett W, Trichopoulos D . Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control. 2000; 11(6):477-88. DOI: 10.1023/a:1008984432272. View

4.
Oken M, Hocking W, Kvale P, Andriole G, Buys S, Church T . Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011; 306(17):1865-73. DOI: 10.1001/jama.2011.1591. View

5.
de Bekker-Grob E, Rose J, Donkers B, Essink-Bot M, Bangma C, Steyerberg E . Men's preferences for prostate cancer screening: a discrete choice experiment. Br J Cancer. 2013; 108(3):533-41. PMC: 3593568. DOI: 10.1038/bjc.2013.5. View